Latest & greatest articles for covid-19

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on covid-19 or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on covid-19 and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for covid-19

101. What strategies mitigate risk of COVID-19 outbreaks and mortality in long-term care facilities?

What strategies mitigate risk of COVID-19 outbreaks and mortality in long-term care facilities? Rapid Review Update 2: What strategies mitigate risk of COVID-19 outbreaks and mortality in long-term care facilities? | Covid-19 Rapid Review | National Collaborating Centre for Methods and Tools This browser does not support PDFs, or the PDF is too large to render. Please download the PDF:

2021 COVID-19 Rapid Evidence Service

102. Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind, randomized control trial Full Text available with Trip Pro

Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind, randomized control trial CDEI - Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia — CDEI Open Menu Close Menu Open Menu Close Menu Mar 11 Written By Citation: Tang, X. , Feng, Y. M., Ni, J. X., Zhang, J. Y., Liu, L. M., Hu, K., ... & Sun, B. (2021). Early use of corticosteroid (...) may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind, randomized control trial. Respiration , 100 (2), 116-126. DOI: Clinical trials link: Journal impact factor: 3.322 (Respiration) Full PICO and Limitations in text: Population: 86 adult (≥18 years) patients with laboratory confirmed SARS-CoV2 infection and confirmed pneumonia admitted to the general wards for less than 72 hours. Intervention and Comparator Intervention: 43

2021 Covid-19 Drug Evidence Initiative

103. A randomized, double-blind, multicenter clinical study comparing the efficacy and safety of combinations of lopinavir/ritonavir, azithromycin, doxycycline, & hydroxychloroquine for COVID-19 Full Text available with Trip Pro

A randomized, double-blind, multicenter clinical study comparing the efficacy and safety of combinations of lopinavir/ritonavir, azithromycin, doxycycline, & hydroxychloroquine for COVID-19 CDEI - A randomized, double-blind, multicenter clinical study comparing the efficacy and safety of a drug combination of lopinavir/ritonavir-azithromycin, lopinavir/ritonavir-doxycycline, and azithromycin-hydroxychloroquine for patients diagnosed with mild to moderate COVID-19 infections — CDEI Open Menu (...) Close Menu Open Menu Close Menu Mar 11 Written By Citation: Purwati , Budiono, Rachman, B. E., Miatmoko, A., Lardo, S., Purnama, Y. I., Laely, M., Rochmad, I., ... & Indrayani, Y. (2021). A randomized, double-blind, multicenter clinical study comparing the efficacy and safety of a drug combination of lopinavir/ritonavir-azithromycin, lopinavir/ritonavir-doxycycline, and azithromycin-hydroxychloroquine for patients diagnosed with mild to moderate COVID-19 infections. Biochemistry research

2021 Covid-19 Drug Evidence Initiative

104. Proxalutamide significantly accelerates viral clearance and reduces time to clinical remission in patients with mild to moderate COVID-19 Full Text available with Trip Pro

Proxalutamide significantly accelerates viral clearance and reduces time to clinical remission in patients with mild to moderate COVID-19 CDEI - Proxalutamide significantly accelerates viral clearance and reduces time to clinical remission in patients with mild to moderate COVID-19 — CDEI Open Menu Close Menu Open Menu Close Menu Mar 11 Written By Citation: Cadegiani, F. A. , McCoy, J., Wambier, C. G., Vaño-Galván, S., Shapiro, J., Tosti, A., ... & Goren, A. (2021). Proxalutamide significantly (...) accelerates viral clearance and reduces time to clinical remission in patients with mild to moderate COVID-19: results from a randomized, double-blinded, placebo-controlled trial. Cureus , 13 (2). DOI: Clinical trials link: N/A Journal impact factor: N/A Full PICO and Limitations in text: Population: 236 adult patients diagnosed with PCR-confirmed SARS-CoV-2 infection with mild symptoms. Intervention and Comparator Intervention: 171 patients. Proxalutamide 200 mg/day for 15 days or until full COVID-19

2021 Covid-19 Drug Evidence Initiative

105. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial Full Text available with Trip Pro

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial CDEI - Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1) — CDEI Open Menu Close Menu Open Menu Close Menu Mar 8 Written By Citation: Mariette, X. , Hermine, O., Resche-Rigon, M., Porcher, R., Ravaud, P., Bureau, S., ... & Hutt, A. (2021). Effect of anakinra versus usual care (...) in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. The Lancet Respiratory Medicine . DOI: Clinical trials link: Journal impact factor: 25.094 (The Lancet Respiratory Medicine) Full PICO and Limitations in text: Population: 116 patients diagnosed with PCR-confirmed SARS-CoV-2 not requiring admission to the hospital ICU at time of admission and mild-to-moderate COVID-19 pneumonia. Intervention and Comparator Intervention: 59 patients

2021 Covid-19 Drug Evidence Initiative

106. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial Full Text available with Trip Pro

The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial CDEI - The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19 — CDEI Open Menu Close Menu Open Menu Close Menu Mar 8 Written By Citation: Chaccour, C. , Casellas, A., Blanco-Di Matteo, A., Pineda, I., Fernandez-Montero, A., Ruiz (...) -Castillo, P., ... & Fernández-Alonso, M. (2021). The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine , 100720. DOI: Clinical trials link: Journal impact factor: N/A Full PICO and Limitations in text: Population: 24 adult outpatients (18-59 years of age) with a positive PCR for SARS-CoV-2 and compatible symptoms with fever and cough starting

2021 Covid-19 Drug Evidence Initiative

107. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia Full Text available with Trip Pro

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia CDEI - Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine — CDEI Open Menu Close Menu Open Menu Close Menu Mar 4 Written By Note: Interim analyses use data from preliminary or ongoing trials. Efficacy and safety data may change for the final report. Citation: Logunov, D. Y (...) . , Dolzhikova, I. V., Shcheblyakov, D. V., Tukhvatulin, A. I., Zubkova, O. V., Dzharullaeva, A. S., ... & Gam-COVID-Vac Vaccine Trial Group. (2021). Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet . DOI: Phase 3: Journal impact factor: 60.390 (The Lancet) Clinical trial registry link: Vaccine Information: Vaccine Efficacy*: 91.6% reduction in the risk of acquiring COVID-19

2021 Covid-19 Drug Evidence Initiative

108. Methylprednisolone in adults hospitalized with COVID-19 pneumonia Full Text available with Trip Pro

Methylprednisolone in adults hospitalized with COVID-19 pneumonia CDEI - Methylprednisolone in adults hospitalized with COVID-19 pneumonia — CDEI Open Menu Close Menu Open Menu Close Menu Mar 3 Written By Citation: Corral-Gudino, L. , Bahamonde, A., Arnaiz-Revillas, F., Gómez-Barquero, J., Abadía-Otero, J., García-Ibarbia, C., ... & Riancho, J. A. (2021). Methylprednisolone in adults hospitalized with COVID-19 pneumonia. Wiener klinische Wochenschrift , 1-9. DOI: Clinical trials link: Journal (...) group were on average older than those in the control group Sample size was too small to adequately power the study Abbreviations ALT = alanine aminotransferase AST = aspartate aminotransferase BID = twice daily CI = confidence interval Cr = creatinine CrCl = creatinine clearance CRP = C-reactive protein COVID-19 = coronavirus disease ECMO = extracorporeal membrane oxygenation ECG = electrocardiogram FiO2 = oxygen concentration HR = hazard ratio IQR = interquartile range ITT = intention to treat LOC

2021 Covid-19 Drug Evidence Initiative

109. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial Full Text available with Trip Pro

Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial CDEI - Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial — CDEI Open Menu Close Menu Open Menu Close Menu Feb 22 Written By Note: Preprints are preliminary reports of work that have not been certified by peer review (...) . They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information (medRxiv). Citation: Lescure, F. X. , Honda, H., Fowler, R. A., Lazar, J. S., Shi, G., Wung, P., ... & Hagino, O. (2021). Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv . DOI: Clinical trial registry link: Full PICO and Limitations

2021 Covid-19 Drug Evidence Initiative

110. Resumption of Pulmonary Function Testing during the Post-Peak Phase of the COVID-19 Pandemic

. COVID-19: Main modes of transmission. Posted on November 5, 2020. Available from: https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus- infection/health-professionals/main-modes-transmission.html. Accessed on December 9, 2020. 8. Santarpia JL, Rivera DN, Herrera VL, et al. Aerosol and surface contamination of SARS-CoV-2 observed in quarantine and isolation care. Sci Rep. 2020. https://doi.org/10.1038/s41598-020-69286-3. 9 World Health Organization. Modes of transmission (...) , 2020. Available from: https://www.canada.ca/en/public- health/services/diseases/2019-novel-coronavirus-infection/health-professionals/infection-prevention- control-covid-19-second-interim-guidance.html. Accessed on June 12, 2020. 19. World Health Organization. Criteria for releasing COVID-19 patients from isolation. Posted on June 17, 2020. Available from: https://www.who.int/news-room/commentaries/detail/criteria-for-releasing-covid- 19-patients-from-isolation. Accessed on June 18, 2020. 6 20

2021 Canadian Thoracic Society

111. ChAdOx1-S [recombinant] - AstraZeneca COVID-19 Vaccine

ChAdOx1-S [recombinant] - AstraZeneca COVID-19 Vaccine Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1

2021 Health Canada - Drug and Health Product Register

112. Residential care facilities; COVID-19 public health guidance

Residential care facilities; COVID-19 public health guidance Rapid review of public health guidance for residential care facilities Health Information and Quality Authority Page 1 of 50 Rapid review of public health guidance for residential care facilities in the context of COVID-19 Updated on: 16 March 2021 Published: 19 March 2021 Rapid review of public health guidance for residential care facilities Health Information and Quality Authority Page 2 of 50 Version history Version Date Specific (...) updates V1.0 30 March 2020 Date of first rapid review V1.1 31 March 2020 Addition of guidance from Germany, the Communicable Disease Network Australia and Hong Kong Update of conclusion Addition of Table 2 Addition of section on restrictive measures pertaining to residential care facilities V1.2 16 April 2020 Updated to include differences in guidance since the initial review. Review expanded to include information on guidance for residential care facilities with no known cases of COVID-19. V1.3 22

2021 Health Information and Quality Authority

113. Pfizer-BioNTech COVID-19 Vaccine (Tozinameran)

Pfizer-BioNTech COVID-19 Vaccine (Tozinameran) Terms of use - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Terms of use From These Terms of Use govern the access and use of Clinical Information released by Health Canada for non-commercial purposes. By clicking the button “I agree” and accepting these Terms of Use and upon being granted access to the Clinical Information, you, and, if applicable, the organization on behalf of which you

2021 Health Canada - drugs and medical devices

114. Moderna COVID-19 Vaccine (mRNA-1273 SARS-CoV-2)

Moderna COVID-19 Vaccine (mRNA-1273 SARS-CoV-2) Terms of use - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Terms of use From These Terms of Use govern the access and use of Clinical Information released by Health Canada for non-commercial purposes. By clicking the button “I agree” and accepting these Terms of Use and upon being granted access to the Clinical Information, you, and, if applicable, the organization on behalf of which you

2021 Health Canada - drugs and medical devices

115. COVID-19 vaccine (Ad26.COV2-S [recombinant]) - Janssen

COVID-19 vaccine (Ad26.COV2-S [recombinant]) - Janssen Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. 11 March 2021 EMA/146391/2021 EMEA/H/C/005737 COVID-19 Vaccine Janssen (COVID (...) -19 vaccine (Ad26.COV2-S [recombinant])) What is COVID-19 Vaccine Janssen and what is it used for? COVID-19 Vaccine Janssen is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people aged 18 years and older. COVID-19 is caused by SARS-CoV-2 virus. COVID-19 Vaccine Janssen is made up of another virus (of the adenovirus family) that has been modified to contain the gene for making a protein found on SARS-CoV-2. COVID-19 Vaccine Janssen does not contain SARS-CoV-2 itself and cannot

2021 European Medicines Agency - EPARs

116. Introducing a coherent European framework for tuning COVID-19 response measures

Introducing a coherent European framework for tuning COVID-19 response measures Introducing a coherent European framework for tuning COVID-19 response measures Global Navigation Other sites: European Centre for Disease Prevention and Control An agency of the European Union Main Navigation Secondary Navigation Search Search Search Search Introducing a coherent European framework for tuning COVID-19 response measures Introducing a coherent European framework for tuning COVID-19 response measures (...) Technical report 17 Mar 2021 Cite: Introducing a coherent European framework for tuning COVID-19 response measures, 17 March 2021 Stockholm: ECDC; 2021. This document presents a coherent, yet non-prescriptive framework for tuning COVID-19 response measures in the European Union and European Economic Area (EU/EEA). Its aim is to ensure efficiency and encourage public trust and compliance, while continuing to protect the health of European citizens. Executive summary This document describes

2021 European Centre for Disease Prevention and Control - Covid-19 Guidance

117. Guidance for COVID-19 quarantine and testing of travellers

Guidance for COVID-19 quarantine and testing of travellers Guidance for COVID-19 quarantine and testing of travellers Global Navigation Other sites: European Centre for Disease Prevention and Control An agency of the European Union Main Navigation Secondary Navigation Search Search Search Search Guidance for COVID-19 quarantine and testing of travellers Guidance for COVID-19 quarantine and testing of travellers Technical report 12 Mar 2021 Cite: European Centre for Disease Prevention (...) and Control. Guidance for COVID-19 quarantine and testing options for travellers. 12 March 2021. ECDC: Stockholm; 2021. This document provides guidance based on scientific evidence regarding quarantine and testing of travellers in EU/EEA countries in the context of the emergence of SARS-CoV-2 variants of concern (VOCs). It follows the provisions of the Council Recommendation (EU) 2021/119 of 1 February 2021 amending Recommendation (EU) 2020/1475 on a coordinated approach to the restriction of free

2021 European Centre for Disease Prevention and Control - Covid-19 Guidance

118. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Full Text available with Trip Pro

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial CDEI - Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY) — CDEI Open Menu Close Menu Open Menu Close Menu Mar 7 Written By Citation: RECOVERY Collaborative Group. (2021, February 2). Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet . DOI: Clinical trials link (...) = creatinine CrCl = creatinine clearance CRP = C-reactive protein COVID-19 = coronavirus disease ECMO = extracorporeal membrane oxygenation ECG = electrocardiogram FiO2 = oxygen concentration HR = hazard ratio IQR = interquartile range ITT = intention to treat LOC = level of consciousness MAP = mean arterial pressure n = number of patients PaO2 = partial pressure of oxygen p-value = probability value RR = respiratory rate RT-PCR = reverse transcriptase polymerase chain reaction SaO2 = oxygen saturation

2021 Covid-19 Drug Evidence Initiative

119. Current views on the potentials of convalescent plasma therapy (CPT) as Coronavirus disease 2019 (COVID-19) treatment: A systematic review and meta-analysis based on recent studies and previous respiratory pandemics Full Text available with Trip Pro

Current views on the potentials of convalescent plasma therapy (CPT) as Coronavirus disease 2019 (COVID-19) treatment: A systematic review and meta-analysis based on recent studies and previous respiratory pandemics Current views on the potentials of convalescent plasma therapy (CPT) as Coronavirus disease 2019 (COVID-19) treatment: A systematic review and meta-analysis based on recent studies and previous respiratory pandemics - PubMed This site needs JavaScript to work properly. Please enable (...) it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Show account info Close Account Logged in as: username Search: Search Save Email Send to Display options Display options Format Save citation to file Format: Create file Cancel Email citation Subject: 1 selected item: 33621405 - PubMed To: Format: MeSH and other data Send email Cancel Add to Collections

2021 EvidenceUpdates

120. SARS-CoV-2 antigen rapid immunoassay for diagnosis of COVID-19 in the emergency department Full Text available with Trip Pro

SARS-CoV-2 antigen rapid immunoassay for diagnosis of COVID-19 in the emergency department SARS-CoV-2 antigen rapid immunoassay for diagnosis of COVID-19 in the emergency department - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Show account info Close Account Logged (...) Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Biomarkers Actions . 2021 Feb 18;1-10. doi: 10.1080/1354750X.2021.1876769. Online ahead of print. SARS-CoV-2 antigen rapid immunoassay for diagnosis of COVID-19 in the emergency department , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Emergency and Acute Medicine, Campus Mitte and Virchow, Charité - Universitätsmedizin Berlin, Berlin, Germany. 2 Institute of Virology, Charité

2021 EvidenceUpdates